News and events
Precision Oncology Exchange with Dr TJ Slavin
The Precision Oncology Exchange with TJ is a new webinar series that serves as an interactive Q&A forum designed to explore recent oncology research and real-world clinical applications.
Webinar: How ctDNA can assist in critical nonoperative management decisions
Watch an in-depth discussion with Dr Andrea Cercek, lead author of the study, and Dan Edelstein, Vice President and General Manager of Haystack Oncology at Quest Diagnostics, exploring how these results are reshaping cancer care—and what they mean for patients,
Haystack Oncology and Rutgers Cancer Institute Collaborate in a Clinical Study to Examine Haystack MRD as a Guide for Post-Surgical Treatment for Lung Cancer
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with the Rutgers Cancer Institute to evaluate the use of Haystack MRD®, a highly sensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) test, to help optimize
FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the company’s Haystack MRD® test for identifying MRD-positive patients with stage II colorectal
Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at Massachusetts Eye and Ear and Massachusetts General Hospital, world-renowned centers for head and neck and advanced cutaneous oncology. The research collaboration
Two leading oncologists take a deep dive into how groundbreaking advancements are providing a clearer crystal ball for guiding patient care
Oncologists like Dr Doug Flora and Dr Debra Patt are realists. But when they began to use new tools to find cancer that surgery or treatment might have missed, something exciting happened.
Recent events
Join Haystack MRD® at the 2026 ASCO® GI Symposium
We’re excited to participate in the American Society of Clinical Oncology (ASCO®) Gastrointestinal (GI) Cancers Symposium, where leading experts will gather to advance care for GI malignancies through science and
Haystack MRD at SABCS 2025
Haystack MRD® by Quest Diagnostics® will be at the San Antonio Breast Cancer Symposium® (SABCS), taking place December 9 to 12 in San Antonio, Texas. Visit us at Quest Diagnostics
We’ll be at ESMO 2025
Join us at the 2025 European Society for Medical Oncology (ESMO) Congress as we share how Haystack MRD, our tumor-informed ctDNA test, is helping redefine the role of minimal residual